Go Pro
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel Free TTOO Stock Alerts

T2 Biosystems (TTOO) Competitors

T2 Biosystems logo
$0.0002 0.00 (0.00%)
As of 07/24/2026
Compare

TTOO vs. SDCCQ, GMVDF, VRAYQ, AFIB, and UTRS

Should you buy T2 Biosystems stock or one of its competitors? MarketBeat compares T2 Biosystems with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with T2 Biosystems include SmileDirectClub (SDCCQ), G Medical Innovations (GMVDF), ViewRay (VRAYQ), Acutus Medical (AFIB), and Minerva Surgical (UTRS). These companies are all part of the "medical equipment" industry.

How does T2 Biosystems compare to SmileDirectClub?

SmileDirectClub (NASDAQ:SDCCQ) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

0.1% of SmileDirectClub shares are owned by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are owned by institutional investors. 64.7% of SmileDirectClub shares are owned by company insiders. Comparatively, 0.0% of T2 Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

SmileDirectClub has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, T2 Biosystems has a beta of 7.71, meaning that its stock price is 671% more volatile than the broader market.

In the previous week, T2 Biosystems had 1 more articles in the media than SmileDirectClub. MarketBeat recorded 1 mentions for T2 Biosystems and 0 mentions for SmileDirectClub. T2 Biosystems' average media sentiment score of 0.67 beat SmileDirectClub's score of 0.00 indicating that T2 Biosystems is being referred to more favorably in the news media.

Company Overall Sentiment
SmileDirectClub Neutral
T2 Biosystems Positive

T2 Biosystems has lower revenue, but higher earnings than SmileDirectClub. T2 Biosystems is trading at a lower price-to-earnings ratio than SmileDirectClub, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SmileDirectClub$470.74M0.00-$86.40M-$0.13N/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

SmileDirectClub has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
SmileDirectClubN/A N/A N/A
T2 Biosystems -563.16%N/A -174.06%

Summary

T2 Biosystems beats SmileDirectClub on 6 of the 11 factors compared between the two stocks.

How does T2 Biosystems compare to G Medical Innovations?

G Medical Innovations (NASDAQ:GMVDF) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

G Medical Innovations has higher earnings, but lower revenue than T2 Biosystems.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
G Medical Innovations$4.42M0.00-$24.63MN/AN/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

G Medical Innovations has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
G Medical InnovationsN/A N/A N/A
T2 Biosystems -563.16%N/A -174.06%

6.0% of G Medical Innovations shares are owned by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are owned by institutional investors. 37.1% of G Medical Innovations shares are owned by insiders. Comparatively, 0.0% of T2 Biosystems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, T2 Biosystems had 1 more articles in the media than G Medical Innovations. MarketBeat recorded 1 mentions for T2 Biosystems and 0 mentions for G Medical Innovations. T2 Biosystems' average media sentiment score of 0.67 beat G Medical Innovations' score of 0.00 indicating that T2 Biosystems is being referred to more favorably in the news media.

Company Overall Sentiment
G Medical Innovations Neutral
T2 Biosystems Positive

G Medical Innovations has a beta of 28.55, suggesting that its share price is 2,755% more volatile than the broader market. Comparatively, T2 Biosystems has a beta of 7.71, suggesting that its share price is 671% more volatile than the broader market.

Summary

G Medical Innovations beats T2 Biosystems on 5 of the 9 factors compared between the two stocks.

How does T2 Biosystems compare to ViewRay?

ViewRay (NASDAQ:VRAYQ) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

In the previous week, T2 Biosystems had 1 more articles in the media than ViewRay. MarketBeat recorded 1 mentions for T2 Biosystems and 0 mentions for ViewRay. T2 Biosystems' average media sentiment score of 0.67 beat ViewRay's score of 0.00 indicating that T2 Biosystems is being referred to more favorably in the news media.

Company Overall Sentiment
ViewRay Neutral
T2 Biosystems Positive

15.5% of ViewRay shares are held by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are held by institutional investors. 2.5% of ViewRay shares are held by company insiders. Comparatively, 0.0% of T2 Biosystems shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ViewRay has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, T2 Biosystems has a beta of 7.71, meaning that its share price is 671% more volatile than the broader market.

T2 Biosystems has lower revenue, but higher earnings than ViewRay. T2 Biosystems is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$102.21M0.00-$107.33M-$0.31N/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

ViewRay has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
ViewRayN/A N/A N/A
T2 Biosystems -563.16%N/A -174.06%

Summary

T2 Biosystems beats ViewRay on 6 of the 11 factors compared between the two stocks.

How does T2 Biosystems compare to Acutus Medical?

T2 Biosystems (NASDAQ:TTOO) and Acutus Medical (NASDAQ:AFIB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

T2 Biosystems has higher revenue and earnings than Acutus Medical. T2 Biosystems is trading at a lower price-to-earnings ratio than Acutus Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A

In the previous week, T2 Biosystems had 1 more articles in the media than Acutus Medical. MarketBeat recorded 1 mentions for T2 Biosystems and 0 mentions for Acutus Medical. T2 Biosystems' average media sentiment score of 0.67 beat Acutus Medical's score of 0.00 indicating that T2 Biosystems is being referred to more favorably in the media.

Company Overall Sentiment
T2 Biosystems Positive
Acutus Medical Neutral

T2 Biosystems has a beta of 7.71, indicating that its stock price is 671% more volatile than the broader market. Comparatively, Acutus Medical has a beta of 5.67, indicating that its stock price is 467% more volatile than the broader market.

23.2% of T2 Biosystems shares are owned by institutional investors. Comparatively, 56.9% of Acutus Medical shares are owned by institutional investors. 0.0% of T2 Biosystems shares are owned by insiders. Comparatively, 5.2% of Acutus Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Acutus Medical has a net margin of -272.74% compared to T2 Biosystems' net margin of -563.16%. T2 Biosystems' return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
T2 Biosystems-563.16% N/A -174.06%
Acutus Medical -272.74%-311.64%-11.57%

Summary

T2 Biosystems beats Acutus Medical on 7 of the 12 factors compared between the two stocks.

How does T2 Biosystems compare to Minerva Surgical?

T2 Biosystems (NASDAQ:TTOO) and Minerva Surgical (NASDAQ:UTRS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Minerva Surgical has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
T2 Biosystems-563.16% N/A -174.06%
Minerva Surgical N/A N/A N/A

T2 Biosystems has a beta of 7.71, meaning that its stock price is 671% more volatile than the broader market. Comparatively, Minerva Surgical has a beta of 2.92, meaning that its stock price is 192% more volatile than the broader market.

23.2% of T2 Biosystems shares are held by institutional investors. 0.0% of T2 Biosystems shares are held by insiders. Comparatively, 8.5% of Minerva Surgical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Minerva Surgical has higher revenue and earnings than T2 Biosystems. T2 Biosystems is trading at a lower price-to-earnings ratio than Minerva Surgical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A
Minerva Surgical$51.69M0.00-$34.11M-$4.21N/A

In the previous week, T2 Biosystems had 1 more articles in the media than Minerva Surgical. MarketBeat recorded 1 mentions for T2 Biosystems and 0 mentions for Minerva Surgical. T2 Biosystems' average media sentiment score of 0.67 beat Minerva Surgical's score of 0.00 indicating that T2 Biosystems is being referred to more favorably in the media.

Company Overall Sentiment
T2 Biosystems Positive
Minerva Surgical Neutral

Summary

Minerva Surgical beats T2 Biosystems on 6 of the 11 factors compared between the two stocks.

Get T2 Biosystems News Delivered to You Automatically

Sign up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TTOO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TTOO vs. The Competition

Export
MetricT2 BiosystemsSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$4K$41.50M$6.86B$12.25B
Dividend YieldN/A1.08%2.67%9.79%
P/E Ratio0.0017.8327.1423.64
Price / Sales0.0028.68517.0189.03
Price / CashN/A18.8650.5459.64
Price / Book0.008.4910.286.07
Net Income-$50.08M-$16.99M$3.60B$331.99M
7 Day PerformanceN/A-4.36%-1.27%-0.63%
1 Month PerformanceN/A-2.71%-0.37%-2.00%
1 Year PerformanceN/A-19.38%18.30%13.62%

T2 Biosystems Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TTOO
T2 Biosystems
N/A$0.00
flat		N/A-99.3%$4K$7.68MN/A180
SDCCQ
SmileDirectClub
N/AN/AN/AN/A$40K$470.74MN/A2,700
GMVDF
G Medical Innovations
N/A$0.00
flat		N/AN/A$26K$4.42MN/A72
VRAYQ
ViewRay
N/AN/AN/AN/A$18K$102.21MN/A300
AFIB
Acutus Medical
N/AN/AN/AN/A$3K$7.16MN/A340

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TTOO) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
Buy this stock tomorrow
Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...
Chaikin Analytics | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...
SmartAsset | Sponsoredtc pixel